Briefing Note
Why claims drift after evidence review
Healthcare organizations rely on claims about clinical efficacy, safety, and cost-effectiveness. Those claims are supported by evidence. When the evidence moves and the claim doesn’t, the claim drifts — and the organization using it inherits the risk.
Claims don’t stay put
A claim is supported at the moment it is written. Trial data, guideline language, label updates, payer policies, and real-world evidence continue to change after that moment. The claim does not update itself.
The gap between what the evidence now supports and what the claim asserts is claim drift. It is not a quality problem or a process failure. It is structural: claims are written once, evidence changes continuously.
Where drift happens
Most teams encounter claim drift when:
- A payer deck overstates a subgroup finding. The original trial showed benefit in the full cohort. A subgroup analysis looked promising but did not meet statistical significance. The deck presents it as established fact.
- A guideline changes but the claim bank is not updated. The guideline committee narrows a recommendation. The internal claim repository still carries the older, broader language into payer conversations.
- MLR-cleared assets keep using outdated evidence. A label update or safety signal narrows the supported population. The MLR-approved materials were cleared before the update and have not been re-reviewed.
- A formulary argument broadens beyond the studied population. An access argument for one indication is reused for a related indication without confirming the evidence trail.
- A diligence memo relies on an endpoint that later weakens. A new trial readout shows that a secondary endpoint no longer reaches significance. The memo is still in circulation.
Why episodic review misses it
Most organizations review claims on a schedule: quarterly P&T meetings, annual guideline updates, pre-launch diligence. Between reviews, evidence accumulates — new trial results, safety signals, label changes, payer policy shifts.
By the time the review convenes, the claim may already be unsupported. The committee is confirming a position that the evidence no longer holds. The longer the gap between reviews, the more drift accumulates.
What a evidence check catches
A claim supportability evidence check tests whether:
- The stated population still matches the evidence population
- The comparator is still relevant under current practice
- The endpoints still carry the weight the claim assigns them
- Caveats that were present in the original publication are still attached
- The claim has not broadened beyond what the source record supports
- Safety signals or label changes have not narrowed the supported scope
- The claim still holds under the most recent guideline language
The cost of not checking
When an unsupported claim makes it into a payer deck, MLR review, formulary submission, or diligence memo, the cost is not just rework. It is delayed launch timelines, payer pushback, compliance exposure, and loss of reviewer trust in the evidence function.
The review itself becomes harder: the team must reconstruct what the evidence supported at the time the claim was written, then compare it to what the evidence supports now, then decide whether the claim is still defensible. This is slow, error-prone, and unrepeatable without a record of what changed.
What to do
The strongest defense against claim drift is not more frequent manual review. It is a supportability record: a structured trace that tells you what the claim asserted, what the evidence supported at that time, what changed since, and whether the claim is still safe to use as written.
Start with the claim your team relies on and the review window in front of you. Build the record. Re-check when the evidence moves.